Hysteroscopy Procedures Market Size, Share & Trends Analysis Report By Procedure (CPT Code 58558, CPT Code 58353), By End-use (Ambulatory Surgical Centers, Hospitals, Clinics), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global hysteroscopy procedures market size was estimated at USD 4.27 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2023 to 2030. The increasing prevalence of gynecological disorders, such as uterine abnormalities, abnormal uterine bleeding, uterine fibroids, polyps, and other fertility disorders, is a key factor driving the market growth. Moreover, the rising adoption and awareness of minimally invasive surgeries over traditional methods and technological advancements in hysteroscopy devices are other major factors fueling the market growth.

The COVID-19 pandemic had a significant impact on the market. The unprecedented surge of COVID-19 cases globally led to inadequate care for patients suffering from other diseases. Since hospitals were prioritizing emergency procedures and delaying/postponing elective surgeries, including gynecological procedures, it led to a surfeit of patients waiting for their surgeries for months. A CovidSurg Collaborative study published in the National Library of Medicine in October 2020 estimated that around 28.4 million elective surgeries, including 81.7% benign surgeries worldwide, were canceled or postponed in 2020, owing to disruption in medical services caused by the pandemic.

The rising incidence of uterine cancer has increased the number of hysteroscopy procedures, thereby accelerating market growth. According to the National Cancer Institute, more than 845,000 women were suffering from uterine cancer in the U.S. in 2020. Uterine cancer is one of the most dominant gynecological disorders universally and its prevalence is expected to rise at an exponential rate. This upsurge is also driven by the increasing prevalence of obesity, as it increases the risk of uterine cancer. For instance, according to the American Cancer Society, 66,200 new uterine cancer cases are estimated to be diagnosed in 2023, whereas around 13,030 people are likely to lose their lives owing to uterine cancer.

Moreover, a number of government and non-governmental organizations are constantly making efforts to create awareness regarding uterine cancer and women’s health, which is also expected to drive the growth of this market. For instance, in 2020, the World Health Organization has set targets to eliminate cervical cancer as a public health issue by 2030. This includes screening of 70% of women aged 35 and again by 45 with high-performance tests and treatment of 90% of women with pre-cancer. Such initiatives are likely to increase the demand for hysteroscopy in the forecast period.

Nowadays, minimally invasive surgical procedures are gaining popularity owing to the reduced risk associated with these procedures. Minor incisions, reduced postoperative pain, and speedy recovery, are leading to high adoption of these procedures. Hysteroscopy is associated with reduced hospitalizations, faster recovery, and less blood loss. Moreover, hysteroscopy induces fewer complications during surgery and a low risk of abdominal wounds. Thus, an increase in patient preference for noninvasive or minimally invasive treatment and the benefits offered by these techniques are anticipated to boost market growth at a significant rate during the forecast period.

Moreover, several key players are investing in R&D for the launch of innovative surgical instruments. Lately, several technologically advanced hysteroscopes are available in the market and can be customized according to the planned procedure. For instance, in July 2021, Meditrina, Inc. expanded its hysteroscopic product portfolio by launching a disposable auto-resecting device Aveta, and a single-use Aveta Opal hysteroscope which is designed to remove soft endometrial tissues. This new launch will help the firm expand its hysteroscopic tissue resection product portfolio, thereby strengthening its market position. According to the World Health Organization (WHO), approximately 190 million which is roughly 10% of girls and women of reproductive age around the globe are affected by endometriosis. The launch of such products can assist in the early diagnosis and treatment of these diseases.

Furthermore, leading industry players, such as Hologic, Inc.; CooperSurgical, Inc.; Stryker Corp.; Karl Storz GmbH; Medtronic; Delmont Imaging; and Johnson and Johnson Services, Inc., are engaged in intensive R&D activities to manufacture innovative products and are making continuous efforts to introduce technologically sophisticated products to the market. For instance, iCare developed by Delmont Imaging comprises an imaging solution imagyn, which is an advanced hysteroscopy database management application. It enables monitoring of hysteroscopy examination directly on an iPad Pro over private & secured Wi-Fi. In February 2021, VirtaMed launched an authorized combined mixed reality training platform for hysteroscopy and gynecological laparoscopy. Such developments are expected to further boost market growth.

End-use Insights

Based on end-use, the market is categorized into hospitals, clinics, and ambulatory surgery centers (ASCs). The hospitals segment accounted for the largest revenue share of over 52.5% in 2022 due to a significantly high inflow of patients for gynecological procedures as compared to other healthcare settings as hospitals can handle any emergencies that may arise during and after surgical procedures. Moreover, hospitals offer a broad range of treatment options, which is expected to drive the segment over the forecast period. For instance, according to the NCBI, around 30,000 myomectomies are performed annually for leiomyomata (fibroids) in the U.S. Moreover, hospitals are the primary health systems in most countries; therefore, the number of hysteroscopy procedures done at hospitals is relatively higher than in other healthcare settings.

The ambulatory surgical centers (ASCs) segment is expected to exhibit the fastest CAGR of 7.7% during the forecast period from 2023 to 2030. Increased preference for outpatient procedures is anticipated to surge the usage of hysteroscopy procedures in ASCs, boosting the segment growth. Outpatient (ambulatory) hysteroscopy is conducted outside the formal setting of an operation theater in a suitably equipped and staffed treatment room. This offers patient comfort and reduces the required time for diagnostic hysteroscopy. Moreover, it is efficient and economical for both patients and surgeons as the setup includes an examination room and does not require an additional operating suite. Hysteroscopy in the ambulatory setting has shown accuracy and patient acceptability equivalent to inpatient hysteroscopy procedures; hence, ambulatory hysteroscopy is rapidly advancing in the field of gynecological practice.

Procedure Insights

Based on procedure, the market is segmented into CPT codes 58555, 58558, 58562, 58340, 58340, 58563, 58565, 58353, and others. The CPT code 58558 segment accounted for the largest revenue share of 35.5% in 2022. As per the details provided by the American Medical Association (AMA), the current procedural terminology or CPT code, 58558, is a procedural code for medical processes that deal with hysteroscopic procedures and laparoscopic procedures carried out on the Corpus Uteri. The code is used to report or diagnose the cause of abnormal uterine bleeding, such as polyps, fibroids, or cancer. The growth of this segment is anticipated due to the rising prevalence of abnormal uterine bleeding and other gynecological disorders, failure of tests such as ultrasound or MRI, and preference for minimally invasive procedures.

The CPT code 58353 segment is expected to grow at the fastest CAGR of 4.2% during the forecast period. As per the American Medical Association (AMA), the current procedural terminology (CPT) code 58353 is a medical procedural code for thermal endometrial ablation under the introduction procedures on the corpus uteri. It is a procedure that uses heat to remove the lining of the uterus (endometrium) using a device known as thermal endometrial ablation, without hysteroscopic guidance. It is done to reduce or stop excessive or abnormal uterine bleeding.

The advancement in technology and new product launches related to endometrial ablation devices are expected to drive the growth of this segment over the forecast period. For instance, in February 2023, Hologic Inc., a medical technology company, announced the approval of the NovaSure V5 global ablation device (GEA) in Canada and Europe. This development is likely to help in delivering better results for women suffering from various cervical and uterine anatomies.

Regional Insights

North America dominated the global hysteroscopy procedures market with a revenue share of over 38.8% in 2022 and will expand further at a steady CAGR from 2023 to 2030. This can be attributed to favorable government regulations & reimbursement policies, the presence of key market players, growing approval & commercialization of products, and high awareness regarding the availability of diagnostic tests & treatments. Furthermore, the rising demand for minimally invasive procedures and increasing investments in the R&D of gynecological systems are among the factors responsible for the regional market growth.

For instance, in June 2022, UroViu launched the FDA-510k-cleared single-use hysteroscope Hystero-V compatible with their Always Ready endoscopy platform consisting of one reusable handle and three procedure-augmented single-use cystoscopes designed to eliminate the need for reprocessing the equipment to save time to detect abnormal uterine abnormalities. Thus, the ease of access to healthcare technologies, the presence of strong distribution channels, and competition among prominent players related to product innovation are contributing to market growth in this region.

Asia Pacific is expected to grow at the fastest CAGR of 7.8% over the forecast period. The presence of a large patient pool and the growing need for technologically advanced & cost-effective healthcare solutions are among the factors expected to present significant growth opportunities. Moreover, an increase in the number of clinical trials and high R&D investments by global market players to enter untapped markets in Asia Pacific, owing to low-cost services, are high-impact rendering drivers. In November 2022, India Medtronic Private Limited, an owned subsidiary of Medtronic launched their TruClear tissue removal system designed for the effective treatment of uterine abnormalities. The launch of such products is expected to improve treatments in this region and accelerate market growth during the forecast period.

Moreover, the rising prevalence of diseases related to women’s health and the subsequent increase in the number of surgeries are expected to boost the regional market growth over the forecast period. Singapore and South Korea are some of the emerging economies in Asia Pacific. Advancing technology, increasing investments, improving reimbursement scenarios, and growing medical tourism are among the factors expected to drive the region’s growth.

Key Companies & Market Share Insights

Key players are involved in adopting strategies, such as partnerships, mergers & acquisitions, regional expansions, and new product launches, to strengthen their position in the global market. For instance, in 2022, Inovus Medical launched HystAR, a new fidelity hysteroscopy simulator which is a combination of the company’s patented AR technology and cloud-based learning platform with the ordinary haptics of its virtual tissue models to deliver extremely realistic, traced hysteroscopy skills training.

Similarly, in February 2021, CooperSurgical, Inc. acquired AEGEA Medical. The acquisition will help the firm expand its product portfolio in women's health. In addition, in January 2021, Hologic, Inc. launched a Fluent Fluid Management System, a CE-marked system, in Europe. This new system is designed to help maintain consistent intracavity pressure and uterine distention. This launch is expected to help the company strengthen its market position and expand its hysteroscopy product line. Some prominent players in the global hysteroscopy procedures market include:

• Medtronic

• Stryker Corp.

• Hologic, Inc.

• KARL STORZ SE & Co. KG

• Medical Devices Business Services, Inc. (Ethicon, Inc.)

• Olympus Corp.

• Delmont Imaging

• B. Braun Melsungen AG

• Richard Wolf GmbH

• CooperCompanies

• Maxer Endoscopy GmbH

• Boston Scientific Corp.

• MedGyn Products, Inc.

• Lina Medical APS

• Luminelle

• Meditrina, Inc. (Aveta)

Hysteroscopy Procedures Market Report scope

Global Hysteroscopy Procedures Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global hysteroscopy procedures market report based on procedure, end-use, and region:

• Procedure Outlook (Revenue, USD Million, 2018 - 2030)

  • CPT code 58555

  • CPT code 58558

  • CPT code 58562

  • CPT code 58340

  • CPT code 58563

  • CPT code 58565

  • CPT code 58353

  • CPT code 58561, 74740, and more (Others)

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Clinics

  • Ambulatory Surgery Centers (ASCs)

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait